SALT LAKE CITY—Mirza Mansoor Raza, a director at Sera Prognostics Inc. (NASDAQ:SERA), recently sold 100 shares of the company's Class A common stock. The shares were sold at a price of $7.69 each, making the total transaction value $769. The transaction comes as SERA's stock has gained nearly 43% over the past six months, according to InvestingPro data.
This transaction was executed on January 6, 2025, as part of a mandated "sell to cover" arrangement to satisfy tax withholding obligations related to the vesting of restricted stock units. As a result, the sale does not represent a discretionary decision by Mr. Raza. Following this transaction, Mr. Raza holds 6,536 shares directly in the company, maintaining his stake in the $265 million market cap firm.
Sera Prognostics, based in Salt Lake City, specializes in medical laboratory services. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 2.11, though it currently trades above its Fair Value. Get access to 8 additional InvestingPro Tips and comprehensive financial analysis through the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Sera Prognostics released its third quarter financials for the fiscal year 2024, reporting a decrease in net revenue from $42,000 to $29,000. The company's operating expenses rose by 8% to $8.9 million, and its net loss increased by 10% to $7.9 million. Despite these financial challenges, Sera Prognostics is focusing on promoting the adoption of its PreTRM test and anticipates the publication of the PRIME study results. This study is expected to play a significant role in influencing clinical guidelines and payer support. The company also reported a 227% surge in website traffic due to increased accessibility and educational campaigns. Despite the decrease in revenue, Sera Prognostics maintains a strong cash reserve of $74.3 million, projecting its sustainability into 2027. These are just some of the recent developments surrounding Sera Prognostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.